SS-31 vs Humanin

SS-31 (Elamipretide) and Humanin are both research peptides with applications in aging and mitochondrial health, yet they operate through fundamentally different pathways. SS-31 is a synthetic tetrapeptide designed to target the inner mitochondrial membrane, stabilizing cardiolipin and enhancing mitochondrial bioenergetics. In contrast, Humanin is a naturally occurring mitochondria-derived peptide (MDP) encoded by the MT-RNR2 gene, with broad cytoprotective and anti-inflammatory effects. Their differing origins—synthetic versus endogenous—and mechanisms shape their respective research contexts, evidence levels, and potential utility. Understanding these distinctions is critical for researchers deciding which peptide aligns with their specific experimental hypotheses.

SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane, binding to cardiolipin and stabilizing cristae structure. It is being developed by Stealth BioTherapeutics for mitochondrial diseases, heart failure, and age-related mitochondrial dysfunction. It has undergone multiple Phase I–III clinical trials, including the TAZPOWER trial for Barth syndrome.This action enhances electron transport chain efficiency and reduces reactive oxygen species production. Developed by Stealth BioTherapeutics, SS-31 has undergone multiple Phase I–III clinical trials, including the TAZPOWER trial for Barth syndrome and studies in heart failure with preserved ejection fraction. Research suggests it improves mitochondrial function, reduces cardiac dysfunction, and may counteract age-related mitochondrial decline. Key claims include enhanced mitochondrial bioenergetics, cardioprotection, and potential anti-aging effects, supported by a robust clinical evidence base.

Humanin is a 21-24 amino acid mitochondria-derived peptide (MDP) encoded by the MT-RNR2 gene in mitochondrial DNA. It was originally discovered in 2001 for its ability to protect neurons from Alzheimer's disease-related toxicity. Since then, it has been found to have broad cytoprotective, anti-inflammatory, anti-apoptotic, and metabolic effects. Circulating humanin levels decline with age and correlate with longevity in centenarian studies.Discovered in 2001 for its ability to protect neurons from Alzheimer's disease-related toxicity, it has since been shown to exert broad cytoprotective, anti-inflammatory, anti-apoptotic, and metabolic effects. Humanin binds to a putative receptor complex involving gp130 and CNTFR, activating STAT3 and Akt signaling pathways. Circulating humanin levels decline with age and correlate with longevity in centenarian studies. Key claims include neuroprotection against Alzheimer's toxicity, cardioprotection, and improved insulin sensitivity, though evidence is primarily from preclinical models and observational human studies.

Both SS-31 and Humanin are investigated for anti-aging research, reflecting their roles in mitochondrial health and cellular resilience. SS-31 is also studied in metabolic health contexts, particularly for improving mitochondrial function in conditions like heart failure and Barth syndrome. Humanin is additionally explored for cognitive enhancement, given its neuroprotective properties against Alzheimer's-related toxicity. While their applications overlap in aging research, the mechanisms differ: SS-31 directly targets mitochondrial structure and function, whereas Humanin modulates broader signaling pathways involved in stress resistance and inflammation. Researchers should consider these distinctions when designing studies focused on specific aspects of aging or mitochondrial dysfunction.

SS-31 has been generally well-tolerated in clinical trials at tested doses, with common adverse effects including injection site reactions (pain, redness), mild headache, dizziness, and nausea. These findings are based on human data from Phase I–III trials. Humanin, as an endogenous peptide naturally present in human circulation, has no formal human safety data from clinical trials. No adverse effects have been reported in animal studies at tested doses, but the lack of human data limits safety characterization. Researchers should weigh the established tolerability of SS-31 against the theoretical lower risk of an endogenous peptide like Humanin, while acknowledging the evidence gap for the latter.